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Community-based treatment is recommended for endemic populations with urinary schis-
tosomiasis; however, the optimal target group for treatment and retreatment interval have
not been established. Using ultrasound, this study identified subpopulations whose lesions
were most likely to respond to treatment and characterized resurgence of pathology. Ultra-
sound examination of 1202 infected patients was followed by chemotherapy with praziquantel.
A sample of 698 patients was followed for 18 months after treatment. Nearly all types of
bladder pathologies resolved after treatment, regardless of patient’s age or intensity of initial
infection. However, many patients’ upper urinary tract pathologies (62.5%) did not resolve.
During the 18-month follow-up period, reappearance of severe bladder pathologies was rare,
and !10% of persons had resurgence of mild bladder pathologies. For this population, re-
treatment is not needed annually but might be cost effective if given several years later. Con-
firmation from other areas is required before general policies can be formed.
Schistosomiasis is a widespread parasitic infection affecting
200 million people in 74 endemic countries [1, 2]. Schistoso-
miasis is currently widespread in Ghana, where Schistosoma
haematobium is much more common than S. mansoni [2, 3].
The current global control strategy is to reduce morbidity; thus,
more people living in endemic areas have been treated for schis-
tosomiasis through control programs in recent years [1]. After
treatment, lesions generally regress, but determinants of re-
gression and the sequence of regression, reinfection, and re-
surgence of pathology are not well understood [4, 5]. Under-
standing the age-specific reduction and resurgence in morbidity
following community or school-based intervention is essential
in identifying the most appropriate target population for treat-
ment, as well as for formulating a retreatment schedule.
Ultrasound has become a valuable tool with which to assess
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urinary system pathology associated with schistosomiasis [6].
It is safe, rapid, noninvasive, and acceptable and applicable in
field settings, and it enables examinations of large numbers of
people at a relatively low cost per capita [7–11]. Ultrasono-
graphy is the only technique that is feasible at present for field
use to assess the impact of the disease in terms of damage to
organs, the regression of lesions after treatment, and the re-
surgence of pathological lesions due to reinfection [12]. Stan-
dardized criteria for ultrasonographic observations for S. hae-
matobium infection have been established and are in the process
of being refined [6, 13].
The aim of this longitudinal ultrasonographic study was to
assess resolution of S. haematobium–associated pathological le-
sions of the lower and upper urinary tract after treatment and
to detect the resurgence of pathological signs due to reinfection
in relation to age, sex, pretreatment pathology, and intensity
of infection, by means of the standard examination protocols
for S. haematobium recommended by the World Health Or-
ganization (WHO) [14].
Methods
Study population and screening laboratory examinations. The
study was conducted in 8 rural communities in southern Ghana
where S. haematobium was known to be common. Infection with
S. mansoni was not detected in screenings of school children in the
study area. These communities are situated approximately 50 km
northwest of Accra, and all are along the river Densu. Between
August 1992 and June 1993, 2562 (65.5%) of 3912 individuals aged
at least 5 years submitted urine samples for examination (popu-
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lation census was conducted by the study team in June 1992). Of
these, samples from 1453 persons (56.7%) were found to be positive
for S. haematobium by means of a method using a 12-mm Nucleo-
pore filter (Coster, Cambridge, MA) [15]. Intensity of infection was
expressed as the number of eggs per 10 mL of urine for each patient.
One pretreatment urine sample (about 200 mL) was collected from
each study patient between 10 AM and 2 PM because of the circadian
variation of ova output in urine. In addition, we determined ma-
crohematuria by naked eye examination and microhematuria and
proteinuria by means of urine chemical reagent sticks (Hemcom-
bisticks; Ames, Miles-Sankyo, Tokyo). Traveling during the col-
lection period and refusal were the main reasons for nonsubmission
of urine, and the coverage rates of urine collection did not differ
by age group.
Baseline ultrasound examinations. During January–September
1993, all persons identified as infected (1453 patients) were called
for ultrasound examinations using a portable ultrasound machine
(Aloka SSD-500 with standard convex probe [3.5 MHz]; Aloka,
Tokyo). The standard protocol proposed by the WHO workshop
was adopted [14]. Bladder shape, wall thickening, wall irregularity,
(pseudo)polyps, and masses were recorded. If any abnormality of
the kidneys and/or ureters was observed, a postvoiding examination
of these organs was done 0.5–1 h later, and the second examination
data were recorded and used for the analysis. Bladder wall calci-
fication and kidney fibrosis were also recorded. Of the 1202 baseline
patients, 162 (13.5%) were reexamined for a quality control purpose
by an expert recommended by the WHO Working Group on Ul-
trasound in Schistosomiasis-related Pathology.
Estimation of frequency of water contact. To estimate the fre-
quency of water contact, trained community health workers ob-
served community members’ water contact behavior at all major
water contact sites in the study area for a total of 30 days during
a 3-month period in the dry season (when more-intense water con-
tact activities were usually observed). All recorded subjects were
matched with population census ID numbers, and study patients
were identified. Each individual’s total number of visits at water
contact sites during the 30-day observation period was then used
as an indicator for individual water exposure. The observers were
not aware of the patients’ infection and pathological statuses. Three
monthly frequency categories were used for the level of water con-
tact: 0, 1–29, and130 times (more than once per day average water
contact).
Chemotherapy. All school-aged children (aged 5–16 years) in
the study communities were targeted for treatment with prazi-
quantel (40 mg/kg body weight) between August and December
1993. This strategy, in which all school-aged children receive treat-
ment, was recommended by the WHO when the average prevalence
among school-aged children is 150% [16] (this strategy is now being
reevaluated [2, 17]). For study participants 116 years old, only
persons with S. haematobium eggs in a urine sample were treated
(selective chemotherapy).
Follow-up examinations and sampling strategy. Of the 1202
patients examined by ultrasound at baseline, 698 infected patients
were selected for follow-up. This total was stratified to include 140
individuals from each of four pathology-severity categories: (1) no
pathology, (2) mild bladder pathology, (3) severe bladder pathol-
ogy, and (4) ureter and kidney (renal pelvis) dilatation, for each
category of children and adults. Irregularity of the bladder inner
surface and/or !5 mm thickening at the posterior wall were cate-
gorized as mild bladder pathology. Protrusion(s) 11 cm into the
lumen, with a broad or narrow stem(s) (masses or polyps) and/or
15 mm posterior wall thickening were categorized as severe bladder
pathology. All patients with ureter or kidney dilatation with or
without bladder pathologies were grouped as a final category. This
sample size was needed to detect differences in pathological reso-
lution or resurgence if the rates differed between groups by 20%
(x2 approximation for binary outcome measurements, 0.05 for type
I and type II error probability, 20% loss to follow-up). All the
patients in the severe bladder and upper urinary tract pathology
categories were chosen for follow-up examinations, since the num-
bers of children and adults in these categories were close to or less
than the calculated sample size. All adult patients (>20 years old)
in the mild bladder pathology category were also chosen for follow-
up, for the same reason. Children (!20 years old) in the mild blad-
der pathology category were sampled with the proportion 1 to 2
(1:2). The follow-up patients with no pathology were matched with
mild bladder pathology patients by age, sex, and community.
We conducted ultrasound and urine examinations 1, 3, 6, 12,
and 18 months after treatment, using the same ultrasound criteria
as for the first examination. Two urine samples per patient were
collected at each follow-up period, and the geometric means of egg
counts were calculated, to indicate the intensity of infection. All
samples were also tested for macrohematuria, microhematuria, and
proteinuria.
Data analysis. All data were recorded onto standardized re-
cording sheets with drawings of the lesions. The codes for path-
ological grades, as defined by the WHO Cairo Proposals [14], were
entered into a microcomputer. Geometric mean of ( ) eggs perx 1 1
10 mL of urine was used for subgroup-specific intensity of infection.
For statistical analysis, x2 test, Fisher’s exact test, Mantel-Haenszel
test for linear association (M-H linear association test), and one-
way analysis of variance (ANOVA) were used, as appropriate.
We calculated resolution rates by using the subset of the follow-
up patients with a particular pathology at baseline that had re-
solved at follow-up examinations. We calculated resurgence rates
by using the subsets of follow-up patients who did not have an
initial baseline pathology or whose pathologies had resolved and
by examining for subsequent resurgence 12 and 18 months after
treatment, respectively. Relative risks (RRs) of the pathology-spe-
cific resolution and resurgence were calculated for possible risk
factors—for example, age, sex, pretreatment pathologies, pretreat-
ment intensity of infection, and concurrent infection status (egg
excretion).
Results
Ultrasound findings before treatment. A total of 1202
(82.7%) of 1453 infected patients participated in ultrasound
examination before treatment (participation rates did not differ
by sex or age group). The numbers of patients examined at
baseline and at each follow-up period are shown by age group
in table 1. More than half (52.7%) of the infected patients had
abnormalities found by ultrasound. Three hundred nineteen
(26.5%) had mild bladder pathologies and 235 (19.6%) had
severe bladder pathologies. A majority (78.7%) of the severe
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No. (%) of patients examined at posttreatment month
0 (baseline) 1 3 6 12 18
5–9 288 (24.0) 170 (28.8) 187 (27.8) 198 (30.0) 184 (29.3) 174 (29.2)
10–14 291 (24.2) 141 (23.9) 169 (25.1) 172 (26.1) 164 (26.1) 157 (26.4)
15–19 199 (16.6) 83 (14.0) 95 (14.1) 94 (14.2) 86 (13.7) 83 (13.9)
20–29 186 (15.5) 99 (16.8) 115 (17.1) 101 (15.3) 91 (14.5) 92 (15.5)
30–39 104 (8.7) 48 (8.1) 50 (7.4) 49 (7.4) 50 (8.0) 43 (7.2)
401 134 (11.1) 50 (8.5) 57 (8.5) 46 (7.0) 53 (8.4) 46 (7.7)
Total 1202 (100) 591 (100) 673 (100) 660 (100) 628 (100) 595 (100)
bladder pathologies were found in patients !20 years old.
Eighty (6.7%) of the screened patients had upper urinary tract
pathology (all 80 patients had kidney dilatation, and 34 of 80
patients had ureter dilatation). Bladder wall thickening and
irregularity of bladder inner surface were significantly associ-
ated with ureter dilatation (odds ratio [OR] for bladder wall
thickening, 2.4; 95% confidence interval [CI], 1.1–5.1; and OR
for irregularity of bladder inner surface, 2.6; 95% CI, 1.2–5.4),
and kidney dilatation (OR for bladder wall thickening, 2.3; 95%
CI, 1.3–3.8; and OR for irregularity of bladder inner surface,
2.4; 95% CI, 1.5–4.0).
Irregularity of the bladder inner surface and masses or polyps
were associated with age, with younger patients having more
of these pathologies (M-H linear association test, ).P ! .001
Irregularity of bladder inner surface had a peak prevalence
among individuals aged 5–9 years, whereas masses or polyps
had a peak prevalence among individuals aged 10–14 years.
Ureter and kidney dilatation were more frequent in individuals
aged 10–14 and 15–19 years than in individuals aged 5–9 or
>20 years. Male (x2 test, ) and heavily infected patientsP ! .001
had more pathologies, including irregularity of the bladder in-
ner surface, mass or polyp, and ureter or kidney dilatation.
Linear trends were significant for all three pathological changes
by baseline intensity of infection level (M-H linear association
test, ).P ! .001
Calcification was detected in 18 patients and was associated
with increasing age (M-H linear association test, ). OnlyP ! .01
2 cases of pyelon fibroses were detected among 1173 screened
patients (29 of 1202 baseline patients were not screened for
pyelon fibrosis; nonparticipation rates did not differ by age,
sex, or pathology category).
Resolution of urinary tract pathologies after treatment.
Most of the severe bladder pathologies resolved within 1 month,
whereas minor irregularity remained for as much as 3 months.
Two-thirds (29 [69%] of 42) of the upper urinary tract pathol-
ogies were still present at 18 months (figure 1). Overall pa-
thology clearance rates (before resurgence) in the patients aged
5–14 years and in older patients were 95.9% and 89.2%,
respectively.
Resolution rates for all types of bladder pathologies did not
differ by sex or age group 3 months after treatment. However,
for upper urinary tract pathologies, those in school-aged chil-
dren resolved more completely than did those in older individ-
uals 18 months after treatment (46.7% for individuals aged 5–14
years and 26.9% for those aged >15 years). The resolution rates
did not differ by initial intensity of infection or by concurrent
infection status (presence of eggs).
Intensity of infection before and after treatment. At baseline,
geometric mean egg counts were 31, 71, 80, and 133 eggs per
10 mL of urine for the four pathology categories (no pathology,
mild bladder pathology, severe bladder pathology, and upper
urinary tract pathology), respectively. More-severe bladder pa-
thologies had higher geometric mean values of egg output (AN-
OVA, ). A peak intensity of infection was observedP ! .001
among individuals aged 10–14 years (137 [95% CI, 96–196],
ANOVA by age group, ). Mean egg counts were dras-P ! .001
tically reduced (98.3%) 3 months after treatment. After a 6-
month follow-up period, the mean egg count started to increase
slowly, and, by 18 months, the overall mean egg count (3) was
still low (95.0% reduction from baseline level). A higher inten-
sity of infection at 18 months was significantly associated with
younger age (intensity peak in individuals aged 5–9 years: 6
[95% CI, 4–8], ANOVA by age group, ). Mean eggP ! .001
counts during the follow-up examinations did not differ by
pretreatment pathology-severity category. Although egg counts
remained low during follow-up examinations, 224 (37.6%) of
the 595 patients had reinfection at 18 months (58.6% for the
peak age group [5–9 years]). Mean egg counts did not differ
by sex at baseline or at 12 or 18 months after treatment.
Macrohematuria, microhematuria, and proteinuria before and
after treatment. Macrohematuria, microhematuria, and pro-
teinuria were observed in 431 (35.9%), 932 (77.5%), and 896
(74.5%) of the 1202 examined patients, respectively, before
treatment, all of these findings being most common in individ-
uals aged 10–14 years. All were related to the severity of pa-
thology (M-H linear association test, ) and the intensityP ! .001
of infection (M-H linear association test, ). All ratesP ! .001
decreased to very low levels 6 months after treatment, to 0%
(0/660), 14.4% (95/660), and 1.4% (9/660) for macrohematuria,
microhematuria, and proteinuria, respectively. Twelve months
after treatment, no macrohematuria cases were observed among
examined patients. Eighteen months after treatment, 8 (1.3%),
178 (29.9%), and 51 (8.6%) of 595 examined patients had ma-
crohematuria, microhematuria, and proteinuria, respectively.
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Figure 1. Resolution and resurgence of ultrasound pathologies after treatment among patients who attended all examinations, at baseline, 1,
3, 6, 12, and 18 months after treatment ( ).n 5 363
Microhematuria severity level was associated with the severity
of bladder pathology resurgence both 12 and 18 months after
treatment (M-H linear association test, ). ProteinuriaP ! .001
was associated with resurgence of bladder pathology only at
18 months after treatment (Fisher’s exact test, ). TwelveP ! .01
months after treatment, microhematuria occurred most com-
monly among those aged 5–9 years, whereas 18 months after
treatment it occurred most commonly among those aged 10–14
years.
Resurgence of ultrasound pathologies. Mild bladder pa-
thologies (irregularity of the bladder inner surface) reemerged
first, followed, at a very low level, by more-severe pathologies,
that is, wall thickening. Masses and polyps recurred in only 2
patients 18 months after treatment (figure 1).
Among the patients who did not have an initial pathology
or whose pathologies had resolved, 21 (3.4%) of 616 had a
reappearance of irregularity of bladder inner surface, 7 (1.1%)
of 625 had wall thickening, and 3 (0.5%) of 625 had a mass or
polyps 12 months after treatment. At 18 months after treat-
ment, the rates of resurgence were still low, with rates of 9.5%
(56/590), 3.2% (19/594), and 0.3% (2/594) for these respective
pathologic groups. At 18 months after treatment, younger in-
dividuals (aged 5–14 years) showed a higher relative risk of
recurrence of bladder inner surface irregularity and wall thick-
ening than did individuals >15 years old (RR for irregularity:
10 [95% CI, 3.8–28.1]; RR for wall thickening: 6.8 [95% CI,
1.6–29.0]). Patients who had pretreatment bladder pathology
had a higher relative risk of resurgence of bladder inner surface
irregularity and wall thickening than did those who did not
have pretreatment pathology (RR for irregularity: 3.7 [95% CI,
1.8–7.7]; RR for wall thickening: 5.4 [95% CI, 1.2–23.3]). The
resurgence rate for mild bladder pathology was higher among
male (11.4%) than among female (6.5%) patients 18 months
after treatment (x2 test, ). Pretreatment intensity of in-P ! .05
fection level did not, however, alter the rate of the resurgence
of any ultrasound-detected pathologies 18 months after treat-
ment. Those with reinfection 18 months after treatment had a
higher relative risk of having resurgence of bladder inner surface
irregularity and wall thickening compared with those without
reinfection (RR for irregularity: 29 [95% CI, 9.3–92.5]; RR for
wall thickening: 14 [95% CI, 3.3–60.2]). A mass or polyp was
detected in only 2 patients 18 months after treatment.
Resurgence of bladder pathology by age group, 12 and 18
months after treatment. Figure 2 shows the probability of
bladder pathology resurgence 12 and 18 months after treatment
for the four age groups. The Mantel-Haenszel test showed a
linear association of resurgence decreasing as age increased,
both 12 and 18 months after treatment ( ). At the peakP ! .001
age group (5–9 years), 13 (7.1%) of 184 patients had resurgence
of bladder pathologies at 12 months, and 37 (21.3%) of 174
had resurgence at 18 months. Resurgence was not observed in
adults at 12 months and was found in only 1 (0.6%) of 179
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Figure 2. Probability of bladder pathology resurgence and intensity of infection 12 and 18 months after treatment by age group among patients
who did not have initial pathology at baseline or whose pathologies had resolved before examinations at 12 and 18 months after treatment
( at 12 months; at 18 months after treatment).n 5 615 n 5 590
patients 18 months after treatment. The relative risk of bladder
pathology resurgence for the age group 5–14 years versus the
>15-year age group was 16.0 [95% CI, 2.2–118] for 12 months
and 10.3 [95% CI, 3.8–28] for 18 months after treatment. Figure
2 shows that the intensity of infection decreased with increasing
age 12 and 18 months after treatment, respectively.
Resurgence rates 18 months after treatment, by water contact
frequency. Figure 3 shows the resurgence rates by water con-
tact and age group at 18 months. Both age and water exposure
appeared to be factors in the likelihood of recurrence of urinary
pathology, but younger children with frequent water exposure
were at highest risk, whereas older individuals appeared to be
at low risk regardless of frequency of water exposure. The Man-
tel-Haenszel test showed a significant linear association of blad-
der pathology resurgence with water contact level for all ages
combined ( ). There was a borderline significance by theP ! .01
frequency of water contact for the age groups 5–9 and 10–14
years (M-H linear association test, ). Intensity of infec-P ! .10
tion was related to water contact level for all ages combined
(ANOVA, ), for age group 10–14 years (ANOVA,P ! .001
), and for age group >15 years (ANOVA, ).P ! .05 P ! .10
Discussion
Three features distinguish this study of S. haematobium in-
fection: (1) study patients were chosen by population-based
sampling for baseline and follow-up examinations, (2) a rela-
tively large number of patients with differing pretreatment pa-
thologies were followed longitudinally, and (3) the study al-
lowed observation of the pathological resolution and resurgence
after community-based chemotherapy.
The study showed that infected younger children (aged 5–9
years) tended to have milder bladder pathologies and that older
children (aged 10–14 years) had more-severe pathology. These
findings are consistent with a progression of severity through
school-aged children. Furthermore, treatment with praziquan-
tel was nearly universally effective in eliminating bladder pa-
thology from those treated, but older individuals with upper
urinary tract disease were more resistant to resolution of their
pathologies. Resurgence of pathology did occur but tended to
be mild at 18 months after treatment and occurred primarily
in individuals aged 5–9 years. Resurgence of severe pathology
during the 18-month follow-up period was not observed.
Younger children (aged 5–9 years) with frequent water exposure
were at highest risk for bladder pathology resurgence, with the
highest intensity of infection.
Previous community-based ultrasound studies have indicated
that severe bladder pathology occurs in school-aged children
and that this group should be targeted for intervention [7–10].
This study showed that there was a peak of minor bladder wall
pathology at age 5–9 years but that more-severe bladder le-
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Figure 3. Probability of bladder pathology resurgence and intensity of infection by frequency of water contact and age group 18 months after
treatment among patients who did not have initial pathology at baseline or whose pathologies had resolved before examination at 18 months
after treatment ( ).n 5 590
sions—for example, wall thickening 15 mm and masses or pol-
yps—tended to occur in individuals aged 10–14 years. The pre-
vious studies were not able to stratify their results by small
age-group intervals because of smaller sample sizes within the
different pathology categories.
Although the observation periods after treatment varied, the
significant resolution of bladder pathologies within a few
months after treatment has been seen previously [5, 10, 18–21].
Doehring et al. [19] observed the disappearance of severe blad-
der pathologies, that is, wall thickening (15 mm) and polyps,
within 1 month. Devidas et al. [20] reported regression of blad-
der pathologies 10 months after treatment, with no difference
by age, sex, or initial intensity of infection, similar to our results.
Many of the upper urinary tract pathologies did not resolve
during the 18-month follow-up period, and only 37.5% of kid-
ney dilatations were resolved. Others have also observed that
upper urinary tract pathology is less likely to resolve. King et
al. [21] reported delayed clearance of kidney lesions 1 year after
treatment in coastal Kenya. By contrast, others have observed
resolution of lesions, and improvement rates have ranged from
73% to 95% [10, 18, 20]. The age distribution among the various
studies differed, and studies reporting high reversibility included
mostly children. Data from the present study suggest that upper
urinary tract pathology in younger children is more responsive
to treatment than that of older children and adults. This is the
expected finding if long-standing pathology results in fibrosis
and scarring, a condition less likely to respond to praziquantel.
There are only a few well-designed population-based sample
studies using ultrasound to assess the long-term morbidity pat-
tern in the endemic population after community-based che-
motherapy. King et al. [22] reported that resurgence rates of
urinary tract lesions remained at a very low level even 2 years
after discontinuing chemotherapy. A recent longitudinal study
showed that some severe pathology requiring treatment ap-
peared at 18 months, and the incidence increased to 11% at 24
months [5]. Some control programs found that annual retreat-
ment was effective for populations at risk [22, 23]. In our study,
younger children (aged 5–9 years) showed the highest resur-
gence rates, and a decreasing trend of resurgence was observed
with age. Even for this age group, !10% of the children had
resurgence 12 months later, and one-fifth of the children had
recurrence of mainly mild bladder lesions 18 months after
treatment.
Some studies have argued that water-contact patterns may
explain the age-related distribution of schistosomiasis [24, 25].
Our study demonstrates an age-related pattern of water contact.
The epidemiological significance of immunity in human schis-
tosomiasis has been the subject of inconclusive debate. Recent
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studies have confirmed the importance of protective immunity
[26–28]. Therefore, the different resurgence rates among the
different age groups observed among study patients suggests
that exposed children had a higher risk of bladder lesions 12
and 18 months later, but the older patients had a low risk of
resurgence regardless of water exposure, suggesting that these
individuals had developed protective immunity.
Microhematuria as detected by urine reagent strips predicts
well the severity of pathology both before and after community-
based treatment. Gross hematuria and proteinuria are good
predictive indicators for pathology in a pretreatment popula-
tion, but they are less sensitive 12 and 18 months after treat-
ment, when only mild pathologies reappeared. Further studies
using these indicators with a predictive potential for direct mor-
bidity (i.e., pathology) should be encouraged, to evaluate the
long-term effectiveness and cost-effectiveness of feasible control
programs in different endemic areas.
One limitation of our findings is that the study was conducted
in one region of Ghana. Transmission of S. haematobium in
the study area was typical for this parasite, but other geographic
areas might have somewhat different transmission patterns.
Second, the infected populations in other geographic areas may
differ in their immune responses to the parasite, resulting in
differing rates of resurgence. Third, strains of S. haematobium
in other areas could vary in their virulence and their likelihood
of inducing resurgent pathology. Thus, confirmation of these
results in other areas endemic for S. haematobium is needed
before general policies can be formed.
With these reservations, the present study suggests that, in
areas with high rates of infection, such as this area in Ghana,
treatment should be provided to children at the age of admis-
sion to primary school (7–9 years). Retreatment may be needed,
but annual retreatment is not necessary in this setting. The
optimal time for retreatment is not established by the present
study, but the low rate of resurgence with severe pathology
suggests that retreatment might be given at approximately the
time of graduation from primary school (12–15 years). The
timing of this treatment schedule is intended to prevent severe
pathology, and it emphasizes the importance of preventing
schistosomiasis-related disability rather than simply treating
infections.
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